#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Liposarcoma recurrent Kawasaki's disease Cytokine release syndrome MELAS syndrome Vaginal cancer Hyperchylomicronaemia Small intestine adenocarcinoma Meningitis meningococcal Uterine leiomyosarcoma Epilepsy with myoclonic-atonic seizures Deafness bilateral Colitis ulcerative Small for dates baby Adenocarcinoma gastric Phaeochromocytoma More trials…

    Learn about Rare Diseases

    Hyperoxaluria – Basic Information Lymphangioma – Life with Disease Pelizaeus-Merzbacher disease – Diagnostics Angiosarcoma – Basic Information Mantle cell lymphoma stage II – Diagnostics Nodal marginal zone B-cell lymphoma – Trials in Disease Fabry’s disease – Basic Information Rhabdoid tumour – Trials in Disease Angiosarcoma metastatic – Life with Disease Familial amyotrophic lateral sclerosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tecovirimat Dirocaftor Tabelecleucel OMECAMTIV MECARBIL Dulaglutide Magrolimab Linaclotide Arrhenatherum Elatius Metformin Hydrochloride Gebasaxturev Vepdegestrant Hydrocortisone Ph. Eur. Luspatercept Taplucainium Chloride Cocarboxylase Tetrahydrate Febuxostat ZIMISLECEL Ruzasvir POTASSIUM HYDROXIDE [18F]CPFPX More therapies…

    Learn about Your Condition

    Myocardial infarction Cholangitis sclerosing Essential thrombocythaemia Thromboangiitis obliterans Fibrous dysplasia of bone Urethral valves Niemann-Pick disease Leiomyosarcoma recurrent Breast angiosarcoma metastatic Hepatobiliary cancer Pouchitis Pharyngeal cancer stage I Hysterectomy Cancer pain Chondrocalcinosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Mnzlob Zyikwwmn Kxopn 2wm Djhxydrfr 4hxxg Hznycgd

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Immune-mediated myositis
    Investigated Drugs:
    • Mycophenolic Acid
    • Cyclophosphamide
    • Fludarabine Phosphate
    Austria Belgium Czechia Finland France Germany +7

  • Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

    Not recruiting

    3 1
    Investigated Drugs:
    • Rocatinlimab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Alpelisib
    • Gedatolisib
    • Dexamethasone
    Austria Belgium Bulgaria Czechia France Germany +6

  • Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Semaglutide
    Austria Belgium Bulgaria Czechia Denmark Finland +15

  • Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Etanercept
    • Adalimumab
    • Baricitinib
    Austria Belgium Czechia Denmark France Germany +9

  • A study to evaluate the efficacy and safety of MET097 in people with obesity or overweight.

    Not recruiting

    3 1
    Bulgaria Czechia Germany Hungary Poland Romania +2

  • A study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • VOROLANIB
    • Aflibercept
    Czechia Germany Hungary

  • A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

    Not recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

    Not recruiting

    3 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Belantamab Mafodotin
    • Dexamethasone
    • Dexamethasone Ph. Eur.
    Belgium Bulgaria France Germany Greece Hungary +4
Previous Page
1 … 21 22 23 24 25 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!